The data here presented suggest that pediatric patients suffering from T-ALL could benefit from the use of NKG2D-CAR T cells, although other treatment strategies targeting LICs compartment may be needed to completely eradicate leukemia. The gene discussed is KLRK1; the disease is acute lymphoblastic leukemia.